- Home
- NMRA
as 11-03-2025 9:44am EST
Stocks
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Upcoming Earnings Alert:
Get ready for potential market movements as Neumora Therapeutics Inc. NMRA prepares to release earnings report on 06 Nov 2025.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 291.5M | IPO Year: | 2023 |
| Target Price: | $7.43 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.61 - $14.09 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Neumora Therapeutics Inc. (NMRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Burow Kristina | NMRA | Director, 10% Owner | Oct 27 '25 | Buy | $2.61 | 1,915,700 | $4,999,977.00 | 6,046,907 | |
| ARCH Venture Partners XII, LLC | NMRA | 10% Owner | Oct 27 '25 | Buy | $2.61 | 1,915,700 | $4,999,977.00 | 6,046,907 | |
| ARCH Venture Partners X, LLC | NMRA | 10% Owner | Oct 27 '25 | Buy | $2.61 | 1,915,700 | $4,999,977.00 | 6,046,907 |
Latest Neumora Therapeutics Inc. News
NMRA Breaking Stock News: Dive into NMRA Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
Neumora Therapeutics (NMRA): Evaluating Valuation Following Dual Pipeline Advances in Psychiatry and Obesity
Insider Monkey
3 days ago
Needham Lifts PT on Neumora Therapeutics (NMRA) to $8 From $6, Keeps a Buy Rating
MT Newswires
4 days ago
Neumora Therapeutics Insider Bought Shares Worth $4,999,977, According to a Recent SEC Filing
Simply Wall St.
5 months ago
Undervalued Opportunities: 3 Penny Stocks With Market Caps Above $30M
GuruFocus.com
6 months ago
Neumora Therapeutics Inc (NMRA) Q1 2025 Earnings Call Highlights: Advancing Brain Disease ...
GlobeNewswire
6 months ago
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Simply Wall St.
6 months ago
Will Neumora Therapeutics (NASDAQ:NMRA) Spend Its Cash Wisely?
GlobeNewswire
6 months ago
Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
Compare NMRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NMRA Neumora Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.